ClinicalTrials.gg
TerminatedNCT06315725AFS_T1DUpdated Oct 6, 2026

Effect of Artificial Sweetener (AFS) on Glucose Metabolism in Patients With Type 1 Diabetes (T1D)

An observational study in Type 1 Diabetes (T1D) and Healthy Subjects, sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre. Terminated at 1 site in Canada. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre · Observational

How we know

Why this study was terminated
The study was terminated due to recruitment difficulties. Only three participants enrolled within two years due to specific insulin pump requirements. Recruitment was therefore discontinued before the planned sample size was reached.
Updated Oct 6, 2026Now TerminatedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-crossover
Time perspective
Other
Enrollment
3
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Diabetes Mellitus, Type 1 by McGill University Health Centre/Research Institute of the McGill University Health Centre — 7 open to participants now, 7 under way, 5 of them phase 3. Diabetes Mellitus, Type 1 · McGill University Health Centre/Research Institute of the McGill University Health Centre.

Started
2024
with 2 others
Observational
3 of 15
1 open now
Registered
11th of 15
by date

Among the 15 studies in Diabetes Mellitus, Type 1 by McGill University Health Centre/Research Institute of the McGill University Health Centre, this one is one of 3 that started in 2024, is one of 3 observational ones, and was the 11th registered.

Diabetes Mellitus, Type 1

3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

7 of the 15 studies in Diabetes Mellitus, Type 1 by McGill University Health Centre/Research Institute of the McGill University Health Centre are open now, in 2 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Diabetes Mellitus, Type 1 by McGill University Health Centre/Research Institute of the McGill University Health Centre, or all of them as a file.
02

Study summary

The goal of this randomized crossover study is to test the prediction that consuming carbohydrates will affect insulin release differently depending on whether Non-Nutritive Sweeteners (NNSs) are consumed simultaneously. We aim to determine whether the predicted effects are associated with oral or post-oral sweet taste receptor signaling,. Our study will focus on patients diagnosed with type 1 diabetes (T1D) who are using an artificial pancreas (AP) system, as it allows us to monitor glucose and insulin levels over time.

Participants will drink four different flavored beverages, some with sweet taste blockade and some without, in a counter-balanced order. They will then rate the sweetness of each beverage, and we will collect data from their AP system to monitor insulin and glucose level.

To achieve this, we will conduct a pilot study to assess the effectiveness and best timing of sweet taste blockade in healthy individuals. Insights gained from the pilot study will inform the main study.

Sucralose will be used as the NNS, maltodextrin as the carbohydrate, and Gymnema Sylvestre (GS) as the sweet taste receptor blocker.

03

Conditions studied

  • Type 1 Diabetes (T1D)
  • Healthy Subjects

Keywords

  • Type 1 Diabetes
  • Artificial Pancreas
  • Artificial Sweeteners
  • Non-Nutritive Sweeteners
  • Cross-Over
  • Taste Perception
  • Indirect Calorimetry
  • Insulin
  • Glucose Metabolism
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

For the pilot study, 10 healthy participants will be recruited. For the main study, 15 potential participants with T1D will be recruited.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with a diagnosis of T1D
  • ≤ 8 %
  • Insulin pump therapy
  • Adults of any gender or biological sex aged 18-45 years old,
  • (BMI) between 18.5-29.9 kg/m,
  • Non-smokers,
  • English or French speaker. ●. Who can consume chicken and fish

Exclusion criteria

Exclusion Criteria:

  • A major medical diagnosis that could potentially influence metabolic dysfunction
  • A major medical diagnosis other than T1D,
  • Alcohol or substance use disorder,
  • Eating disorder or history of malabsorptive syndrome,
  • Inflammatory bowel disease,
  • Self-reported impairment in taste or smell,
  • A known taste or smell dysfunction (e.g., anosmia),
  • Active pregnancy and/or lactation,
  • Food allergies or intolerances,
  • Dislike of the test beverages,
  • History of bariatric surgery at any point in the past ●. Regular consumer of Gymnema sylvestre
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Observational model
Case-crossover
Time perspective
Other
Enrollment
3 participants (actual)
Patient registry
No

Interventions

  • OtherSweet taste perception with/without sweet taste blockade

    In our study, we will use our four different novel flavored beverages, with and without a sweet taste blockade.

06

What researchers measure

Primary outcomes

  1. Effectiveness and optimal time course of sweet test blockade on sweet taste perception in healthy individuals

    our aim is to test whether the impact of consuming NNS with carbohydrates on glucose metabolism is related to oral or post-oral sweet taste receptor signaling.

    Time frame: from enrollment to the end of treatment at 4 weeks

  2. Mean plasma glucose, basal and bolus insulin changes in individuals with T1D on AP following beverage consumption.

    Consuming NNS alongside carbohydrates affects glucose metabolism differently compared to carbohydrates alone in participants with type 1 diabetes (T1D) using an artificial pancreas (AP) system for exogenous insulin production

    Time frame: From enrollment to the end of treatment at 4 weeks

Secondary outcomes

  1. Resting Energy Expenditure (REE) and nutrient partitioning changes in individuals with T1D on AP following beverage consumptionT1D on AP following beverage consumption

    To test whether the co-ingestion of the NNS with carbohydrate can result in changes in post-ingestion metabolism, we plan to employ indirect calorimetry (IC) to evaluate resting energy expenditure (REE) before and after flavoured beverages consumption.

    Time frame: from enrollment to the end of treatment at 4 weeks

07

Study locations

1 site
  • Center for Innovative Medicine, The Research Institute of the McGill University Health Centre
    Montreal, Quebec H4A 3J1, Canada
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Nov 2024 to primary completion in Sep 2026, 22 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 6, 2026: primary completion Nov 2025 → Sep 2026 and completion Dec 2027 → Sep 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 12, 2024
First posted
Mar 18, 2024
StartActual
Nov 12, 2024
Primary completionActual
Sep 22, 2026was Nov 2025
CompletionActual
Sep 22, 2026was Dec 2027
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Terminated The study was terminated due to recruitment difficulties. Only three participants enrolled within two years due to specific insulin pump requirements. Recruitment was therefore discontinued before the planned sample size was reached.
changed Oct 6, 2026
Primary completion
Nov 1, 2025→Sep 22, 2026 (actual)
Oct 6, 2026
Study completion
Dec 1, 2027→Sep 22, 2026 (actual)
Oct 6, 2026
Enrollment
25 (estimated)→3 (actual)
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    Recruiting→Terminated
    Why stopped The study was terminated due to recruitment difficulties. Only three participants enrolled within two years due to specific insulin pump requirements. Recruitment was therefore discontinued before the planned sample size was reached.
    Primary completion Nov 1, 2025→Sep 22, 2026 (now actual)
    Study completion Dec 1, 2027→Sep 22, 2026 (now actual)
    Enrollment 25 (estimated)→3 (actual)
    + 6 other changes: identifiers, verification date, oversight details, contact details, site details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06315725
Responsible party
Dana Small (Professor, McGill University Health Centre/Research Institute of the McGill University Health Centre) — Principal investigator
First posted
Mar 18, 2024
Start date
Nov 12, 2024
Primary completion
Sep 22, 2026
Completion
Sep 22, 2026
Last update
Oct 6, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion